Cargando…
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
BACKGROUND: BAF312 (Siponimod) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. This drug is currently undergoing clinical trials for the treatment of secondary progressive multiple sclerosis (MS). Here, we investigated the effects of BAF312 on isolated astrocyte and micr...
Autores principales: | O’Sullivan, Catherine, Schubart, Anna, Mir, Anis K., Dev, Kumlesh K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746808/ https://www.ncbi.nlm.nih.gov/pubmed/26856814 http://dx.doi.org/10.1186/s12974-016-0494-x |
Ejemplares similares
-
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016) -
Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights
por: Bigaud, Marc, et al.
Publicado: (2021) -
The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis
por: Hundehege, Petra, et al.
Publicado: (2019) -
Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy
por: Mekhaeil, Marianna, et al.
Publicado: (2023) -
Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures
por: Pritchard, Adam J., et al.
Publicado: (2014)